Expanded access: opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases

被引:8
|
作者
Ozdinler, P. Hande [1 ,2 ,3 ,4 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Neurol, 303 E Chicago Ave, Chicago, IL 60611 USA
[2] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Ctr Dev Therapeut, Chem Life Proc Inst, Evanston, IL USA
[3] Northwestern Univ, Mesulam Ctr Cognit Neurol & Alzheimers Dis, Feinberg Sch Med, Chicago, IL 60611 USA
[4] Northwestern Univ, Feinberg Sch Med, Les Turner ALS Ctr, Chicago, IL 60611 USA
关键词
AD; ALS; disease mechanisms; drug discovery; PD;
D O I
10.1111/febs.15529
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In neurodegenerative diseases, a select set of neuron population displays early vulnerability and undergoes progressive degeneration. The heterogeneity of the cerebral cortex and the heterogeneity of patient populations diagnosed with the same disease offer many challenges for developing effective and long-term treatment options. Currently, patients who are considered to have a 'rare' disease are left with no hopes for cure, and many of the neurodegenerative diseases progress fast without any effective solutions. However, as our understanding of disease mechanisms evolve, we begin to realize that the boundaries between diseases are not as sharp as once believed. There are many patients who develop disease due to common underlying causes and mechanisms. As we move forward with drug discovery effort, it becomes obvious that we will have to shift our focus from finding a cure for a disease, to finding solutions to the disease-causing cellular mechanisms so that patients can be treated by mechanism-based strategies. This paradigm shift will lay the foundation for personalized medicine approaches for neurodegenerative disease patients and patients diagnosed with a rare disease.
引用
收藏
页码:1457 / 1461
页数:5
相关论文
共 50 条
  • [41] Personalized medicine in patients with Osteogenesis imperfecta
    Oliver Semler
    Heike Hoyer-Kuhn
    Joerg Doetsch
    Eckhard Schoenau
    Molecular and Cellular Pediatrics, 1 (Suppl 1)
  • [43] A movement monitoring system for patients of neurodegenerative diseases
    Gugliandolo, G.
    Sciva, A.
    Campobello, G.
    Capra, P. P.
    Marino, S.
    Bramanti, A.
    Di Lorenzo, G.
    Bramanti, P.
    Donato, N.
    2018 IEEE INTERNATIONAL INSTRUMENTATION AND MEASUREMENT TECHNOLOGY CONFERENCE (I2MTC): DISCOVERING NEW HORIZONS IN INSTRUMENTATION AND MEASUREMENT, 2018, : 1159 - 1164
  • [44] Apolipoprotein E genotyping in patients with neurodegenerative diseases
    Ballering, LAP
    SteffensNakken, HM
    Esselink, RAJ
    DeVos, RAI
    Steur, RNHJ
    Vermes, I
    CLINICAL BIOCHEMISTRY, 1997, 30 (05) : 405 - 411
  • [45] Drawing analysis in the assessment of patients with neurodegenerative diseases
    Sitek, Emilia J.
    Narozanska, Ewa
    Konieczna, Seweryna
    Brockhuis, Bogna
    Wieczorek, Dariusz
    Wszolek, Zbigniew K.
    Slawek, Jaroslaw
    NEUROLOGY, 2017, 88 (02) : 218 - 219
  • [46] Some immunological parameters in patients with neurodegenerative diseases
    Lahunskiy, D
    Poleshchuk, V
    Muravina
    Morozov, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S273 - S274
  • [47] Cognition and Cognitive Training in Patients with Neurodegenerative Diseases
    Cavallo, Marco
    Lasaponara, Stefano
    BRAIN SCIENCES, 2025, 15 (02)
  • [48] Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases
    Lynn Marie Trotti
    Elias G. Karroum
    Current Neurology and Neuroscience Reports, 2016, 16
  • [49] Altered Pupil Dynamics in Patients with Neurodegenerative Diseases
    Huang, Jeff
    Coe, Brian
    Smorenburg, Matthew
    Brien, Donald
    Black, Sandra
    Finger, Elizabeth
    Freedman, Morris
    Lang, Anthony
    Strong, Michael
    Swartz, Richard
    Tartaglia, Carmela
    Zinman, Lorne
    Munoz, Douglas
    NEUROLOGY, 2020, 94 (15)
  • [50] New tools for the evaluation of patients with neurodegenerative diseases
    Dickerson, Bradford C.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2014, 4 (06) : 403 - 405